<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927573</url>
  </required_header>
  <id_info>
    <org_study_id>GEM3PSCA-01</org_study_id>
    <nct_id>NCT03927573</nct_id>
  </id_info>
  <brief_title>Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker</brief_title>
  <official_title>A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GEMoaB GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GCP-Service International Ltd. &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GEMoaB GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This dose-escalating phase I trial assesses for the first time the safety, the side effects&#xD;
      and the harmlessness, as well as the therapeutical benefit of the new study drug GEM3PSCA in&#xD;
      patients with prostate stem cell antigen (PSCA) expressing cancer types which failed to&#xD;
      respond to standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation scheme; Single patient cohorts on the first three dose levels, 3+3 afterwards.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>End of Treatment (EOT) +14 days (DLT period)</time_frame>
    <description>MTD is the previous dose level of the cohort where a DLT is observed in at least wo subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and intensity of adverse events</measure>
    <time_frame>End of Treatment (EOT) +14 days (DLT period)</time_frame>
    <description>graded according to CTCAE V4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose limiting toxicity (DLT)</measure>
    <time_frame>End of Treatment (EOT) +14 days (DLT period)</time_frame>
    <description>Dose Limiting Toxicity is defined as any event at least possibly related to investigational medicinal product (IMP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended phase 2 dose (RP2D)</measure>
    <time_frame>From start of treatment until up to 14 days after last treatment cycle (2 initial cycles + max. 6 additional cycles per patient). Each cycle consists of 7 days treatment plus DLT evaluation period (14 days)</time_frame>
    <description>The RP2D will be determined based on MTD, all available efficacy data, and all available safety data, including information derived from additional treatment cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of GEM3PSCA according to RECIST1.1 (Response Evaluation Criteria in Solid Tumors)</measure>
    <time_frame>End of Treatment (EOT) +14 days (DLT period)</time_frame>
    <description>response rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen (PSA) response in patients with prostate cancer</measure>
    <time_frame>End of Treatment (EOT) +14 days (DLT period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>End of Treatment (EOT) + 14 days (DLT period)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Renal Cancer</condition>
  <condition>Transitional Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>GEM3PSCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of GEM3PSCA, a PSCA targeted bispecific antibody engaging T-cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GEM3PSCA</intervention_name>
    <description>Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles</description>
    <arm_group_label>GEM3PSCA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients, ≥ 18 years of age&#xD;
&#xD;
          2. PSCA positive cancer (i.e. urogenital tract (renal, transitional cell, prostate),&#xD;
             non-small cell lung, breast and pancreatic cancer) refractory to standard treatments&#xD;
             and with no other available standard or curative treatment&#xD;
&#xD;
          3. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             version 1.1&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
          5. Life expectancy of at least 2 months&#xD;
&#xD;
          6. Platelets &gt; 50,000/µl&#xD;
&#xD;
          7. Hemoglobin &gt; 9 g/dl&#xD;
&#xD;
          8. Adequate renal and hepatic laboratory assessments&#xD;
&#xD;
          9. Adequate pulmonary function with oxygen saturation (SpO2) &gt; 89 % and no structural&#xD;
             pulmonary disease which might jeopardize patient safety according to judgement of the&#xD;
             investigator&#xD;
&#xD;
         10. Left ventricular ejection fraction (LVEF) of ≥ 45 %&#xD;
&#xD;
         11. Existing port-system or central venous catheter resp. acceptance of implantation of a&#xD;
             device&#xD;
&#xD;
         12. A female of childbearing potential may be enrolled providing she has a negative&#xD;
             pregnancy test at screening visit and is routinely using a highly effective method of&#xD;
             birth control resulting in a low failure rate (e.g. hormonal contraception,&#xD;
             intrauterine device, total sexual abstinence or sterilization) until 3 months from the&#xD;
             last study drug administration. Male patients must also practice a highly effective&#xD;
             method of birth Control&#xD;
&#xD;
         13. Able to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other malignancy requiring active therapy&#xD;
&#xD;
          2. Non-measurable tumor disease&#xD;
&#xD;
          3. Patients with brain metastases&#xD;
&#xD;
          4. Use of chemotherapy and radiotherapy within 2 weeks prior to start of trial medication&#xD;
&#xD;
          5. Use of checkpoint inhibitors (having a marketing authorization) within a washout of 5&#xD;
             x t1/2 (half-life); patients with experimental checkpoint inhibitors at all&#xD;
&#xD;
          6. Other investigational drug within the past 4 weeks before start of trial medication&#xD;
&#xD;
          7. Patients undergoing renal dialysis&#xD;
&#xD;
          8. Pulmonary disease with clinical relevant hypoxia&#xD;
&#xD;
          9. Evidence of active, non-infectious pneumonitis or history of interstitial lung disease&#xD;
&#xD;
         10. Cardiac disease: i.e. heart failure NYHA (New York Heart Association) III or IV,&#xD;
             unstable coronary artery disease&#xD;
&#xD;
         11. Active central nervous disease (e.g. Parkinson, multiple sclerosis, seizures) and&#xD;
             stroke within last 6 months&#xD;
&#xD;
         12. Active gastrointestinal ulceration or bleeding within the last 6 months unless related&#xD;
             to underlying malignant disease&#xD;
&#xD;
         13. Renal outflow obstruction, macroscopic or significant microscopic hematuria&#xD;
&#xD;
         14. Active infectious diseases considered by investigator to be incompatible with protocol&#xD;
&#xD;
         15. Major surgery within 28 days&#xD;
&#xD;
         16. Autoimmune diseases requiring steroids at a dose above 10 mg prednisolone equivalent&#xD;
             or other immunosuppressants&#xD;
&#xD;
         17. Pregnant or breastfeeding women&#xD;
&#xD;
         18. Psychiatric disorders, drug and/or alcohol abuse&#xD;
&#xD;
         19. Known history of human immunodeficiency virus (HIV) or active/chronic infection with&#xD;
             hepatitis C virus (HCV) or hepatitis B virus (HBV)&#xD;
&#xD;
         20. Known hypersensitivity to GEM3PSCA excipients&#xD;
&#xD;
         21. Evidence suggesting that the patient is not likely to follow the study protocol (e.g.&#xD;
             lacking compliance)&#xD;
&#xD;
         22. Incapability of understanding purpose and possible consequences of the trial&#xD;
&#xD;
         23. Patients who should not be included according to the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Bargou, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Würzburg, CCC Mainfranken</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ariane Klemm</last_name>
    <phone>+49 351 4466 4500</phone>
    <phone_ext>0</phone_ext>
    <email>gem3psca-01@gemoab.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martina Raupach</last_name>
    <phone_ext>0</phone_ext>
    <email>gem3psca-01@gemoab.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Lorenzen, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Sylvie Lorenzen, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariele Goebeler, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Ralf Bargou, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Metzelder, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Stephan Metzelder, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Wermke, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Martin Wermke, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gunhild von Amsberg, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

